Healthcare Industry News: Cumberland Pharmaceuticals
News Release - December 18, 2007
Cumberland Pharmaceuticals Announces AppointmentsNASHVILLE, Tenn., Dec. 18 (HSMN NewsFeed) -- Cumberland Pharmaceuticals is pleased to announce the appointment of two senior executives.
David L. Lowrance has been promoted to Vice President and Chief Financial Officer. In this role, he is responsible for overseeing the company's accounting and financial activities, including financial reporting and planning. Mr. Lowrance has 17 years of financial and accounting experience, joining Cumberland in 2003 as Director of Finance and Accounting. He spent eight years with two global conglomerates, including four years as senior vice president for Icore International. Prior to this, Mr. Lowrance spent four years at Ernst & Young, LLP. A graduate of the University of Georgia, he is a certified public accountant.
Doug Jack has joined the company as Senior Manager of SEC Reporting. He is responsible for the preparation of all SEC-required financial reports. Mr. Jack brings more than 14 years of accounting and financial experience to his position. Prior to joining Cumberland, he spent eight years as audit manager with Ernst & Young and PricewaterhouseCoopers, and served as CFO and controller at Southern Specialty Brands. A certified public accountant, he is a graduate of the University of Georgia.
"We are fortunate to work with these outstanding individuals who bring great depth of experience and knowledge in their respective areas," said A.J. Kazimi, Cumberland's Chief Executive Officer. "Each will play an important role in taking the company to the next level as we continue to grow and capitalize on opportunities created by the shifting pharmaceutical landscape."
About Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. Cumberland's primary target markets include hospital acute care and gastroenterology. Cumberland markets Acetadote® for the treatment of acetaminophen poisoning and Kristalose®, a prescription strength laxative. The Company is also developing Amelior® which is in Phase III studies for the treatment of both pain and fever. Cumberland is dedicated to providing innovative products which improve quality of care for patients.
Source: Cumberland Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.